The Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to DNA Topoisomerase Inhibitors

Abstract— Intragenic tandem duplications in the FLT3 gene (FLT3-ITD) are one of the most common genetic abnormalities in acute myeloid leukemia (AML) and are associated with a poor prognosis, which has led to the introduction of new-generation FLT3 inhibitors, including quizartinib, into clinical practice as part of combination therapy regimens. Given the heterogeneity of the clonal composition of AML in terms of the proportion of FLT3-ITD-positive (FLT3-ITD(+)) and FLT3-ITD-negative (FLT3-ITD(–)) clones, the effect of FLT3 inhibition on the sensitivity of various leukemic cell subpopulations to DNA-damaging chemotherapeutic agents remains poorly understood. This study demonstrates that pretreatment of FLT3-ITD(–) THP-1 AML cells with quizaritinib at non-toxic concentrations increases their resistance to the cytotoxic effects of etoposide and topotecan, whereas no such protective effect is observed in FLT3-ITD(+) MV4-11 cells. The results obtained in this study suggest that quizaritinib, as part of combination chemotherapy, may contribute to the development of drug resistance in FLT3-ITD(–) AML subclones to DNA-damaging agents by arresting proliferation in the late G2/M phase and shifting the balance of pro- and anti-apoptotic proteins of the Bcl-2 family toward survival, a factor that must be taken into account when developing targeted therapy regimens with FLT3 inhibitors.

Authors

Institutions

Publication Details

Journal
Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology
Published
2026-11-18
DOI
https://doi.org/10.1134/s1990747826700273
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to DNA Topoisomerase Inhibitors

А. С. Сенотов, Ya. V. Lomovskaya, K. S. Krasnov, Р. С. Фадеев et al.
2 links
Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology
Acute Myeloid Leukemia Research
article

The Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to DNA Topoisomerase Inhibitors

А. С. Сенотов, Ya. V. Lomovskaya, K. S. Krasnov, Р. С. Фадеев, Irina V Odinokova, A. I. Zvyagina, M. I. Kobyakova, A. S. Didenko, E. I. Mescheryakova
article en

Abstract

Abstract— Intragenic tandem duplications in the FLT3 gene (FLT3-ITD) are one of the most common genetic abnormalities in acute myeloid leukemia (AML) and are associated with a poor prognosis, which has led to the introduction of new-generation FLT3 inhibitors, including quizartinib, into clinical practice as part of combination therapy regimens. Given the heterogeneity of the clonal composition of AML in terms of the proportion of FLT3-ITD-positive (FLT3-ITD(+)) and FLT3-ITD-negative (FLT3-ITD(–)) clones, the effect of FLT3 inhibition on the sensitivity of various leukemic cell subpopulations to DNA-damaging chemotherapeutic agents remains poorly understood. This study demonstrates that pretreatment of FLT3-ITD(–) THP-1 AML cells with quizaritinib at non-toxic concentrations increases their resistance to the cytotoxic effects of etoposide and topotecan, whereas no such protective effect is observed in FLT3-ITD(+) MV4-11 cells. The results obtained in this study suggest that quizaritinib, as part of combination chemotherapy, may contribute to the development of drug resistance in FLT3-ITD(–) AML subclones to DNA-damaging agents by arresting proliferation in the late G2/M phase and shifting the balance of pro- and anti-apoptotic proteins of the Bcl-2 family toward survival, a factor that must be taken into account when developing targeted therapy regimens with FLT3 inhibitors.

Biochemistry (Moscow) Supplement Series A Membrane and Cell BiologyVol. 20(4)
Russian Academy of Sciences (RU), Lomonosov Moscow State University (RU), Institute of Theoretical and Experimental Biophysics (RU), Institute of Cell Biophysics (RU)
Russian Academy of Sciences
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon